SCHEMBL185767

SCHEMBL185767

NS(=O)(=O)c1ccc(Cl)s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES2 Q9H7Z7 1/20 0.53
CA2 P00918 7/20 0.47
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA9 Q16790 2/20 0.46
ALDH1A1 P00352 4/20 0.44
KMT2A Q03164 4/20 0.44
HTT P42858 2/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 3/20 0.42
TDP1 Q9NUW8 1/20 0.42
MEN1 O00255 1/20 0.42
TSHR P16473 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL185389 0.98 PTGES2 (0.51) PTGES2CA2CA12CA1CA9
SCHEMBL13991610 0.87 CA2 (0.45) PTGES2CA2CA12CA1CA9
SCHEMBL27697968 0.84 PTGES2 (0.46) PTGES2CA2CA12CA1CA9
SCHEMBL4413809 0.79 CA2 (0.46) PTGES2CA2ALDH1A1KMT2AHTT
SCHEMBL4152423 0.78 KMT2A (0.46) PTGES2ALDH1A1KMT2AHTTGAA
SCHEMBL19269 0.78 KMT2A (0.46) PTGES2ALDH1A1KMT2AHTTGAA
SCHEMBL8870484 0.76 CA2 (0.52) CA2CA12CA1CA9L3MBTL1
SCHEMBL301650 0.76 KMT2A (0.46) PTGES2ALDH1A1KMT2AHTTGAA
SCHEMBL11404135 0.76 KMT2A (0.44) PTGES2ALDH1A1KMT2AHTTGAA
SCHEMBL10050617 0.76 L3MBTL1 (0.47) PTGES2ALDH1A1KMT2AHTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 406 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119528773-A N-alkylation method of sulfonamide compound 赣南医科大学 2025-02-28 CN claimed
CN-118344351-A Preparation method and application of PET imaging agent targeting neuroinflammatory purinergic P2Y12 receptor 复旦大学 2024-07-16 CN claimed
WO-2024115549-A1 ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-06 WO claimed
CN-114614058-A Thin-layer composite proton exchange membrane and preparation method and application thereof 中国石油化工股份有限公司 2022-06-10 CN claimed
CN-114432903-A Composite membrane with acid resistance and preparation method and application thereof 中国石油化工股份有限公司 2022-05-06 CN claimed
CN-111646973-A Polysubstituted quinazoline derivative and preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2020-09-11 CN claimed
CN-111303146-A 3-cyanopyridine compound, pharmaceutical composition containing same, preparation method and application thereof 中国科学院上海药物研究所 2020-06-19 CN claimed
WO-2020119590-A1 3-CYANOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USES THEREOF. 中国科学院上海药物研究所 2020-06-18 WO claimed
CN-101516837-A Sulfonamide derivatives HOFFMANN LA ROCHE (CH) 2009-08-26 CN claimed
US-6730470-B2 SENSITIVITY, HIGH DEVELOPING SPEED AND LITTLE PERFORMANCE FLUCTUATION DUE TO VARIATION OF HEAT DEVELOPMENT TEMPERATURE FUJI PHOTO FILM CO., LTD. (JP) 2004-05-04 US claimed
US-20020086251-A1 Photothermographic material FUJIFILM CORPORATION (JP) 2002-07-04 US claimed
CN-122010656-A Application of oxyalkylisourea in introducing methyl and isotopically-labeled methyl 陕西师范大学 2026-05-12 CN disclosed
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2026-03-19 US disclosed
US-20250197360-A1 NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE BARUCH S. BLUMBERG INSTITUTE 2025-06-19 US disclosed
CN-119528773-A N-alkylation method of sulfonamide compound 赣南医科大学 2025-02-28 CN disclosed
CN-1268123-A Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO (JP) 2000-09-27 CN disclosed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP disclosed
EP-0995742-A1 SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-26 EP disclosed
US-5302724-A Thiophenesulfonylureas; anticarcinogenic agents ELI LILLY AND COMPANY (US) 1994-04-12 US disclosed
EP-0467613-A1 Antitumor compositions and methods of treatment ELI LILLY AND COMPANY (US) 1992-01-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer TP53, HIF1AN, MDM2 PTGES2 2534/4885CA2 535/4885CA12 2734/4885
US-20250197360-A1 NOVEL DIAZEPINES THAT TARGET YELLOW FEVER VIRUS NON-STRUCTURAL 4B (NS4B) PROTEIN AND THEIR METHOD OF USE CUL4B, BRD4, CUL4A PTGES2 3015/4885CA2 4723/4885CA12 4515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.